Novel beta-thalassemia treatment shows promise in preclinical tests

St. Jude Children’s Research Hospital researchers have identified a possible new use for the drug rapamycin: Activating a cellular pathway to reduce accumulation of a toxic protein that is a hallmark of β-thalassemia.

Memphis, Tennessee, August 21, 2019

Mitchell Weiss, MD, PhD

Mitchell J. Weiss, M.D., Ph.D., Faculty Member; Arthur Nienhuis Endowed Chair in Hematology, St. Jude Children’s Research Hospital

Mondira Kundu

Mondira Kundu, M.D., Ph.D., Associate Member, Faculty in the Departments of Pathology, Cell and Molecular Biology, St. Jude Children’s Research Hospital

Rapamycin, a drug widely used to protect organ transplant patients, eased symptoms of β-thalassemia in mice and showed promise for treatment of humans with the inherited disorder, researchers reported. St. Jude Children’s Research Hospital investigators led the study, which appears online today in the journal Science Translational Medicine.

Researchers showed that rapamycin worked by activating a protein quality-control pathway—the autophagy pathway—in cells. That reduced the accumulation of the toxic proteins that destroy red blood cells in individuals with β-thalassemia. Untreated, the buildup leads to fewer red blood cells, anemia, fatigue and other symptoms, including an enlarged spleen, heart and liver, and fragile bones.

“There is an urgent need for better drugs to treat the many thousands of people born worldwide each year with β-thalassemia,” said Mitchell Weiss, M.D., Ph.D., chair of the St. Jude Department of Hematology. He and Mondira Kundu, M.D., Ph.D., of the St. Jude Department of Pathology and Department of Cell and Molecular Biology, are the corresponding authors.

“Rapamycin won regulatory approval almost 20 years ago,” Weiss said. “The drug can be safely administered and is relatively inexpensive. Given that, and the findings from this study, our next objective is to design a small clinical trial to test the safety and efficacy of rapamycin for treatment of β-thalassemia.”

Research is also underway to identify additional drugs that regulate autophagy.

β-thalassemia

β-thalassemia is one of the most common blood disorders in the world.

The standard treatment, blood transfusion, is not universally available and requires medication to prevent iron overload that is a side effect of treatment. While many patients with β-thalassemia are living longer and enjoying a better quality of life, disease-related morbidity and mortality is still substantial.

β-thalassemia is caused by mutations in the HBB gene that disrupts production of the protein hemoglobin, which red blood cells use to ferry oxygen throughout the body. Hemoglobin has four protein chains—two α-globin and two β-globin. β-thalassemia patients make lower than normal levels of β-globin, in some cases none. The free α-globin accumulates and disrupts red blood cell production.

Reducing free α-globin

Researchers knew rapamycin inhibited mTOR, a protein that inactivates the enzyme ULK1. In this study, the scientists reported that β-thalassemic mice lacking the Ulk1 gene had an approximately two-fold increase in α-globin accumulation compared to mice with the Ulk1 gene.

“Rapamycin inhibition of mTOR can activate ULK1,” said first author Christophe Lechauve, Ph.D., of the Weiss laboratory. “β-thalassemic mice treated with rapamycin showed a significant reduction in α-globin accumulation and ineffective erythropoiesis along with a longer life span for red blood cells.”

Rapamycin also reduced levels of free α-globin in immature red blood cells, erythroblasts, in individuals with β-thalassemia.

The project grew from a long-standing collaboration among the St. Jude researchers and co-authors Irene Motta, M.D., and M. Domenica Cappellini, M.D., of the University of Milan, Italy.

The study’s other authors are Julia Keith, Stephanie Fowler, Kalin Mayberry, Abdullah Freiwan, Emilio Boada Romero, Jinghui Zhang and Heather Tillman, of St. Jude; Eugene Khandros and Christopher Thom of the Children’s Hospital of Philadelphia; and Paola Delbini of the University of Milan.

The research was funded in part by grants (DK61692, HL114697) from the National Institutes of Health; the EMBO long-term fellowship and ALSAC, the fundraising and awareness organization of St. Jude.

Read the Research Highlight.

St. Jude Children's Research Hospital

St. Jude Children's Research Hospital is leading the way the world understands, treats and cures childhood cancer and other life-threatening diseases. It is the only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children. Treatments developed at St. Jude have helped push the overall childhood cancer survival rate from 20 percent to 80 percent since the hospital opened more than 50 years ago. St. Jude freely shares the breakthroughs it makes, and every child saved at St. Jude means doctors and scientists worldwide can use that knowledge to save thousands more children. Families never receive a bill from St. Jude for treatment, travel, housing and food — because all a family should worry about is helping their child live. To learn more, visit stjude.org or follow St. Jude on social media at @stjuderesearch.

 

St. Jude Media Relations Contacts

Marvin Stockwell
Desk: (901) 595-6384
Cell: (901) 734-8766
marvin.stockwell@stjude.org
media@stjude.org

Michael Sheffield
Desk: (901) 595-0221
Cell: (901) 275-9065
michael.sheffield@stjude.org
media@stjude.org